期刊文献+

房颤患者纤溶系统的变化及其临床意义

Changes of plasma fibrinolytic parameters and their clinical significance in patients with atrial fibrillation.
下载PDF
导出
摘要 目的探讨非瓣膜性房颤患者纤溶系统的变化及其临床意义。方法选择2004年8月至2005年1月在我院就诊的100例非瓣膜性房颤患者,根据是否发生缺血性脑卒中(简称脑卒中)分为两组,房颤1组为未发生脑卒中者,房颤2组为发生脑卒中者,每组50例。入选同期50例健康体检者为正常对照组。对房颤患者和健康者测定血浆中组织型纤溶酶原激活物(t!PA)、纤溶酶原激活物抑制剂!1(PAI!1)、纤维蛋白原(Fg)。结果单因素分析结果显示:房颤1组和房颤2组患者的血浆t!PA、PAI!1、Fg水平显著高于对照组(P<0.001);房颤2组患者的血浆t!PA、Fg水平显著高于房颤1组(P<0.05﹚;PAI!1水平在两组房颤患者间无显著性差异。多因素分析结果显示:t!PA、PAI!1、Fg水平均与卒中发生显著相关。结论房颤患者纤溶活性降低,发生脑卒中者的低纤溶状态较房颤无脑卒中者更为明显,这可能是房颤患者易发生脑卒中的机制之一。 Objective To investigate the changes of plasma fibrinolytic parameters in patients with nonvalvular atrial fibrillation and to explore their clinical significance. Methods One hundred patients with nonvalvular atrial fibrillation were divided into 2 groups, one group without stroke (groupl, n=50) and the other with stroke (group 2, n=50). The healthy control group included 50 healthy subjects. Plasma tissue plasminogen activator (t-PA) level and plasminogen activator inhibitor type-1 (PAI-1) level were assayed using enzyme-linked immunoassay. Fibrinogen (Fg) were measured. Resuits In univariate analysis, compared with the healthy control group, patients with atrial fibrillation had significant increase of Plasma t-PA ,PAI-1 and Fg level. Plasma t-PA and Fg level was higher in group 2 than that in groupl. There was no significant difference in the level of PAI-1. In multivariate analysis, t-PA, PAI-1 and Fg were associated with stroke. Conclusions Patients with atrial fibrillation are at a hypofibrinolytic state, especially in group 2. This may contribute to the increased risk of stroke.
出处 《北京医学》 CAS 2006年第6期347-350,共4页 Beijing Medical Journal
关键词 心房颤动 脑血管意外 纤溶系统 Atrial fibrillation Cerebrovascular accident Plasma fibrinolytic parameters
  • 相关文献

参考文献9

  • 1Wolf PA,Abbott RD,Kennel WB.Atrial fibrillation as an independent risk factor for stroke:the Framingham study.Stroke,1991,22:983-988.
  • 2Lip GY.The prothrombotics state in atrial fibrillation:new insight,more question,and clear answers needed.Am Heart J,2000,140:348-350.
  • 3Fuster VRL,Asinger RW.ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation:Executive summary a report of the american college of cardiology/american heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the north Aamerican society of pacing and electrophysiology.Circulation,2001,104:2118-2150.
  • 4Catherin L,David E,Newby DE,et al.Fibrinolytic actions of intraarterial angiotensin Ⅱ and bradykinin in vivo in man.Cardiov Res,2000,47:707-714.
  • 5Mitusch R,Siemens H J,Garbe M,et al.Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy.Thromb Haemost,1996,75:219-223.
  • 6Ortuno MF,Schiling RV,Vera MP,et al.Improvement in fibrinolytic function following anticoagulant treatment in chronic rtheumatic atrial fibrillation.Rev Esp Cardion,1999,52:25-30.
  • 7王志坚,赵水平.心力衰竭患者纤溶参数变化及药物干预效果的评价[J].中国循环杂志,2002,17(1):38-40. 被引量:13
  • 8Minamino T,Kitakaze M,Sanada S,et al.Increased expression of P-selection on platelets in a risk factor for silent cerebral infarction in patients with atrial fibrillation:role of nitric oxide.Circulation,1998,98:1721-1727.
  • 9Li-Saw-Hee FL,Blann AD,Lip GY.Effects of fixed low-dose warfarin,aspirin -warfarin combination therapy,and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation.Stroke,2000,31:828-833.

二级参考文献7

  • 1[1]Catherin L,David E,Newby,et al.Fibrinolytic actions of intra-arterial angiotensin Ⅱ and bradykinin in vivo in man.Cardiov Res,2000,47:707-714.
  • 2[2]Douglas E,Vaughan jean L,Gean L,et al.Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction.Circulation, 1997,96:442-447.
  • 3[3]Chritopher R,Gibbs M,Andrew D,et al.Abnormalities of hemorheological endothelial and pulatelet in patients with chronic heart failure in sinus rhythm,Effects of angiotensin-converting enzyme inhibit and β-blocker therapy.Circulation,2001,103:1746-1751.
  • 4[4]Nicholas ER,Goodfield MB,David E,et al.Effect of acute angiotensin Ⅱ type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patient with heart failure.Circulation,1999,99:2983-2985.
  • 5[5]Douglas E,Vaughan S,Lazos,et al.Angiotensin Ⅱ regulates the rexpression of plasminogen activator inhibitor-1 in cultured endothelial cell.J Clin Invest,1995,95:995-1001.
  • 6[6]Ridker P,Cynthia L,Gaboury,et al.Stimulation of plasminogen activator inhinbitor in vivo by the fusion of angiotensin Ⅱ,Evidence of a potential interaction between the rennin-angiotensin system and fibrinolytic function.Circulation,1993,87:1969-1973.
  • 7[7]Nancy J,Brown MD,James V,et al.Bradykinin stimulates tissue plasminogen activator release from human forearm vasculatue through B2 recepto-dependent,NO synthase-independnt and cyclooxygenase-independent pathway.Circulation, 2000,102:2190-2196.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部